戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rosis, Paget's disease, bone metastasis, and hypercalcemia of malignancy.
2 (PTHrP) is the agent responsible for humoral hypercalcemia of malignancy.
3  immune deficiency mice and produced humoral hypercalcemia of malignancy.
4 as the tumor product responsible for humoral hypercalcemia of malignancy.
5 vered as a tumor product that causes humoral hypercalcemia of malignancy.
6 , the drug was approved for the treatment of hypercalcemia of malignancy.
7 tivity in a syngeneic tumor model of humoral hypercalcemia of malignancy.
8 phonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases.
9 g as a novel therapeutic approach in humoral hypercalcemia of malignancy and possibly multiple myelom
10                                      Humoral hypercalcemia of malignancy (HHM) is caused by the secre
11 se associated with breast cancer and humoral hypercalcemia of malignancy (HHM) that occurs with or wi
12 imately 80% of ATLL patients develop humoral hypercalcemia of malignancy (HHM), a life-threatening co
13 ized as the major causative agent of humoral hypercalcemia of malignancy (HHM).
14 us type-1 (HTLV-1) infection develop humoral hypercalcemia of malignancy (HHM).
15                        In a model of humoral hypercalcemia of malignancy in which PTHrP secreted by s
16    The potent effects of OPG in this humoral hypercalcemia of malignancy model suggest a potential th
17                                      Humoral hypercalcemia of malignancy results from the effects of

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。